Cannvas MedTech (CSE:MTEC) (Frankfurt:3CM) (OTC:CANVF), a leading digital cannabis education and analytics company, is pleased to establish a working partnership with US Cannabis Pharmaceutical Research and Development (“US Cannabis”), a resource for organizations seeking to normalize, legalize and develop medicinal cannabis. The deal positions Cannvas as an exclusive, leading provider of cannabis education and analytics to US Cannabis and its vast network of clients.

“As the global cannabis industry grows and the need for an arm’s length third-party organization to provide unbiased education and information around all aspects of cannabis becomes more apparent, we’re proud to partner with US Cannabis as their leading source of trusted cannabis-related learning,” said Shawn Moniz, Chief Executive Officer, Cannvas MedTech. “This deal is structured to further our growth plans for 2019 while significantly expanding the reach of our educational and analytics platforms into the United States, a projected $23.4 billion market for recreational cannabis by 2022 and $8 billion for medicinal by 2024 according to BDS Analytics.”

A key partnership for both organizations, Cannvas and US Cannabis will work together to deliver cannabis education to potential and active cannabis consumers through the Cannvas.Me digital learning resource. Cannvas will reinforce US Cannabis’ goal of normalizing and developing medicinal and therapeutic cannabis through US Cannabis’ vast partner network across the United States. Both companies believe educating the public about the investment, business and job opportunities around cannabis legalization will complement strengthened education on the plant’s potential health benefits, and the Cannvas.Me platform is well-positioned to meet that challenge.

“Over the next 5 years, the global cannabis industry will grow faster than any other industry in the world,” says Michael Patterson, CEO of US Cannabis.  “Accurate data analytics and education from a trusted source are critical to the development of global standards of this new legal industry. Cannvas provides the best platform to use with our clients in the United States and abroad to facilitate consistent training, increased compliance with local, state, and federal laws, and create awareness of the consumer base locally and globally. We are proud to work with Cannvas to develop the gold standard for cannabis operations and compliance.”

US Cannabis provides services to help an array of clients – from startups to seasoned investors, established operations to Native American tribes and government agencies. Cannvas will support these efforts through the licensing of educational software, the use of cannabis data and analytics to better understand key industry trends and drivers for the businesses with whom US Cannabis works closely, placement of Cannvas educational kiosks in existing US-based dispensaries and clinics, and other elements designed to elevate the level of learning Americans experience around cannabis. With more than a dozen states expected to pass new cannabis laws by 2025, according to New Frontier Data, the projected growth of the American cannabis market will provide many more opportunities for US Cannabis and Cannvas to work together as this partnership evolves.

About US Cannabis Pharmaceuticals

US Cannabis serves as a resource for organizations seeking to normalize, legalize and develop medicinal cannabis by engaging in commerce, marketing, regulatory reform and product/process development. Its mission is to move society forward through legalized cannabis. It believes the most powerful form of advocacy is commerce and the best way to promote cannabis is by working together to create a robust industry. US Cannabis seeks to achieve these objectives by helping clients ensure they meet licensing requirements, comply with regulations and effectively manage their operations to ensure success for all stakeholders. For more information, please visit

About Cannvas MedTech Inc.

Cannvas MedTech is a leading digital cannabis education and analytics company providing accessible and evidence-based education while harnessing the power of cannabis data and analytics to deliver deeper insights into consumer behaviour and paint a clearer picture of cannabis consumption across Canada.

No stock exchange or securities regulatory authority has reviewed or accepted responsibility for the adequacy or accuracy of this release.

Some of the statements contained in this release are forward-looking statements, such as estimates and statements that describe the Issuer’s future plans, objectives or goals, including words to the effect that the Issuer or management expects a stated condition or result to occur. Since forward-looking statements address future events and conditions, by their very nature, they involve inherent risks and uncertainties.  For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company’s Management’s Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted

For further information: or visit

Related Links

Click here to connect with Cannvas MedTech (CSE:MTEC) (Frankfurt:3CM) (OTC:CANVF) for an Investor Presentation. 


Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) announces it has completed a first closing of a non-brokered private placement of up to $2,000,000. The Company accepted subscriptions for 13,740,000 units at a price of $0.05 per unit, for gross proceeds of $687,000. Each unit consists of one common share and one common share purchase warrant. Each warrant entitles the holder to purchase one additional common share at $0.075 for a period of two years from the date of closing, subject to the option of the Company to accelerate the expiry date in the event that its shares trade at $0.15 or more for 10 consecutive days

The Company paid $18,000 in cash and issued 160,000 warrants on the same terms as noted above to qualified finders. Securities issued pursuant to this tranche are subject to trading restrictions until April 5, 2021. The Company is expecting to complete the financing by December 16, 2020. Proceeds will be used for working capital and to fund future investments.

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”), announces that further to its press release dated December 3, 2020, the TSX Venture Exchange has approved the repricing of 19,405,804 warrants of the Company that were originally issued on July 27, 2018, to $0.10. These warrants are set to expire on December 31, 2020.

For anybody wishing to exercise these Warrants, please contact the Chief Executive Officer, Terry Donnelly at the particulars below.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN), Aurora Cannabis (NYSE: ACB) (TSX: ACB), and HEXO Corp. (NYSE: HEXO)

Cannabis leaders are focusing on innovation in premium branding, global expansion, and tight operational execution in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders:

Keep reading... Show less

TransCanna Holdings Inc. (CSE: TCAN) (FSE: TH8) (“TransCanna” or the “Company”) is pleased to announce that it has closed the 2nd and final tranche of its Unit financing. In connection with the closing, the Company issued 1,356,873 Units at a price of $0.55 per Unit, for gross proceeds of $746,280.15. Each Unit consists of one (1) common share and one (1) warrant. Each warrant entitles the holder to purchase one common share of the Company, at an exercise price of $0.75 per share, for a period of two years from the date of issuance. The warrants are subject to an acceleration right that allows the Company to give notice of an earlier expiry date if the Company’s share price on the CSE (or such other stock exchange the Company’s shares may be trading on) is equal to or greater than $1.25 for a period of 20 consecutive trading days. Finder’s fees of $42,542, 3,200 Finder’s shares and 80,550 Finder’s warrants were issued in connection with finder’s fees payable.

In total, the Company raised gross proceeds of $1,757,180 and issued 3,194,873 Units.

Keep reading... Show less

 Sweet Earth Holdings Corp. (CSE: SE) (FSE: 1KZ1) (OTCQB: SEHCF) (“Sweet Earth” the “Company”) is pleased to announce that it has received full Depository Trust Company (“DTC”) eligibility in the United States. On October 20, 2020, Sweet Earth announced that its shares had been listed on the United States’ Over-The-Counter Bulletin (“OTCQB”) under the ticker SEHCF.

DTC status means that Sweet Earth shares are now eligible to be transferred between brokerage accounts within the United States and significantly augments the ease in which American-based investors are able to trade Sweet Earth shares.

Keep reading... Show less